Hormone mix may cut breast cancer risk in menopausal women

WASHINGTON - A right mix of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, can significantly reduce breast cancer risk in menopausal women, say researchers

Women in menopause who have symptoms are currently treated with a combination of estrogen plus progestin hormone therapy, however this treatment comes with side effects, including a higher risk of breast cancer caused by the progestin.

Yale researchers sought to determine a better way of administering hormone therapy without the breast cancer risk.

During the study, lead researcher Dr Hugh S. Taylor, professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale, and his colleagues treated breast and endometrial cell lines with either estrogen or estrogen plus one of the SERMs.

They later looked at various markers of cell growth, including proliferating cell nuclear antigen (PCNA), one of the best-characterized markers of cell growth.

The team found that PCNA was increased when they stimulated cells with estrogen and decreased when they added a SERM, indicating that the SERM blocked cell growth.

Taylor said that breast and uterine cells won’t be stimulated by the estrogen plus SERM combination, so women in menopause get the benefits of estrogen without the risk of progestin.

Progestin is a double-edged sword, Taylor said. It poses a breast cancer risk, but if you use estrogen alone without progestin, there is a higher risk of uterine cancer. Therefore SERMs appear to be a good substitute for progestin.

“In our study, the right combination of estrogen and various SERMs was able to prevent the proliferation of breast and endometrial cells,” said Taylor.

“These preliminary findings could lead to a better way of administering hormone therapy to women in menopause,” he added.

The findings were presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia. (ANI)